DTaP vaccine adult - GlaxoSmithKline

Drug Profile

DTaP vaccine adult - GlaxoSmithKline

Alternative Names: 776423; Boostrix; Refortrix; Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed (Boostrix) - GSK

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diphtheria; Pertussis; Tetanus

Most Recent Events

  • 09 Jun 2016 GlaxoSmithKline Biologicals plans a phase III trial for Diphtheria, Tetanus and Pertussis (In children) in China (IM) (EudraCT2016-000644-34)
  • 23 May 2016 No recent reports on development identified - Phase-III for Diphtheria, Pertussis and Tetanus (In children) in Vietnam (IM)
  • 01 Mar 2016 GlaxoSmithKline completes a phase III trial in Diptheria, Tetanus and Pertussis (Healthy volunteers, Prevention) in USA (NCT00489970)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top